Rumi Therapeutics Secures Option to License Enthorin’s IND-Ready PDE2 Inhibitor for Fragile X Syndrome
Rumi Therapeutics, a drug-development company operating within Rumi Scientific Holdings, has announced an option-to-license agreement with Enthorin Therapeutics to advance RTX-7340, also known as ENT-7340, an investigational phosphodiesterase 2 (PDE2) inhibitor being developed for the potential treatment of Fragile X syndrome (FXS). The agreement adds an investigational therapeutic candidate with an IND-ready preclinical development package to Rumi Therapeutics’ pipeline and marks an important step in the company’s transition from discovery-stage research toward clinical development.
The collaboration brings together Enthorin Therapeutics’ development work on RTX-7340 and Rumi Scientific Holdings’ research capabilities, including its proprietary human organoid platform. The program is intended to build on preclinical findings supporting PDE2 inhibition as a potential therapeutic strategy for Fragile X syndrome, a genetic neurodevelopmental disorder associated with cognitive impairment, behavioral challenges, and abnormalities in brain function.
Through the agreement, Rumi Therapeutics aims to advance RTX-7340 toward clinical evaluation while using complementary research approaches to strengthen the scientific rationale for its development. These approaches include studies in Fragile X disease models, human organoid research, and the evaluation of translational neurophysiological endpoints that could help researchers assess whether the candidate produces measurable changes in brain activity relevant to the disease.
The agreement also supports Rumi Scientific Holdings’ broader strategy of connecting human disease biology with therapeutic development. Although Fragile X syndrome is the initial focus of the RTX-7340 program, Rumi Scientific plans to investigate whether PDE2 inhibition may have relevance to other neurodevelopmental disorders.
Advancing Rumi Therapeutics Toward Clinical Development
The option-to-license agreement represents a strategic milestone for Rumi Therapeutics as it expands its pipeline beyond early-stage discovery research. By securing access to RTX-7340, the company gains an opportunity to advance a candidate supported by an extensive preclinical development package and move toward the next stage of its development pathway.
An Investigational New Drug (IND)-ready candidate has progressed through substantial preclinical work intended to support a potential application to begin clinical testing. However, IND readiness does not mean that a clinical trial has been authorized or that the candidate has demonstrated safety or efficacy in humans. Further regulatory and development steps may be required before human studies can begin.
For Rumi Therapeutics, the agreement provides a foundation for evaluating the potential of PDE2 inhibition in Fragile X syndrome while integrating findings from its broader scientific platform. The company intends to use data from preclinical models and human-relevant research systems to inform its clinical development strategy, including the identification of biological measures that could help assess treatment effects.
Ignacio Muñoz-Sanjuán, PhD, CEO of Rumi Therapeutics, described the agreement as an important step in establishing the company as a clinical-stage drug developer.
“This agreement marks an important step in building Rumi Therapeutics into a clinical-stage company. With RTX-7340, we are combining an IND-ready asset with insights generated through Rumi Scientific’s human organoid platform and a development strategy centered on translation to patients. Fragile X is our initial focus, with opportunities to investigate the relevance of this biology across other neurodevelopmental disorders.”
The company’s strategy centers on combining a defined therapeutic candidate with research capabilities designed to improve the understanding of disease mechanisms and treatment responses. By incorporating human organoid studies and neurophysiological measurements into its development approach, Rumi Therapeutics aims to establish a clearer connection between the candidate’s biological activity and potential clinical outcomes.
Enthorin Therapeutics Partnership Supports RTX-7340 Development
Enthorin Therapeutics brings the RTX-7340 program and its supporting preclinical research into the collaboration. The agreement creates an opportunity for Rumi Therapeutics to build on the existing development package and evaluate the candidate’s potential for clinical investigation in individuals living with Fragile X syndrome.
For Enthorin, the collaboration provides a pathway to advance the program with a partner that has access to human organoid research capabilities and a stated focus on translating disease biology into therapeutic development.
J. Guy Breitenbucher, PhD, managing partner and co-founder of Enthorin Therapeutics, emphasized the complementary nature of the companies’ capabilities.
“We are pleased to partner with Rumi Therapeutics to advance RTX-7340 toward clinical evaluation in Fragile X syndrome. Rumi Scientific’s human organoid capabilities complement the preclinical development work supporting the candidate and create an opportunity to deepen our understanding of its therapeutic potential. Together, we aim to translate that scientific foundation into a focused clinical development program.”
The partnership is designed to bring together preclinical evidence, human-relevant experimental systems, and a development strategy that prioritizes measurable biological effects. These elements may help guide decisions about how RTX-7340 should be evaluated in future clinical studies, subject to further development and regulatory requirements.
The companies’ approach also reflects a broader challenge in developing treatments for neurodevelopmental conditions: demonstrating not only that a drug affects a particular biological pathway, but also that those changes can be measured reliably and are associated with meaningful improvements for patients.
PDE2 Inhibition as a Potential Approach to Fragile X Syndrome
Fragile X syndrome is a genetic condition commonly associated with intellectual disability, developmental delays, learning difficulties, and behavioral or social challenges. It is generally caused by changes involving the FMR1 gene, which can lead to reduced or absent production of fragile X messenger ribonucleoprotein, commonly known as FMRP.
FMRP plays an important role in regulating the production of proteins involved in neuronal development and synaptic function. When FMRP is deficient, the processes responsible for the formation, maturation, and regulation of connections between nerve cells can be disrupted.
These changes can affect synaptic plasticity, the ability of neural connections to strengthen or weaken in response to activity. Synaptic plasticity is important for learning, memory, and the processing of information. Abnormalities in neuronal connectivity and signaling are therefore important areas of investigation in Fragile X research.
PDE2A is an enzyme involved in regulating intracellular signaling pathways through its effects on cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). These signaling molecules participate in multiple cellular processes, including pathways relevant to neuronal communication and plasticity.
Research cited in support of the RTX-7340 program indicates that PDE2A activity is increased in animal models of Fragile X syndrome. Pharmacological inhibition of PDE2 has been associated with improvements in several disease-related measures in these models, including dendritic spine maturation, synaptic plasticity, and social and cognitive endpoints.
Dendritic spines are small structures on neurons that receive signals from other nerve cells and play a central role in synaptic communication. Changes in their development and maturation have been associated with Fragile X-related abnormalities. Investigating whether PDE2 inhibition can influence these structures may therefore help researchers better understand the candidate’s potential mechanism of action.
These preclinical observations provide a scientific rationale for investigating RTX-7340 as a potential treatment approach. Nevertheless, findings in animal models do not establish that the same effects will occur in humans, and the relationship between changes in these biological measures and improvements in daily functioning remains to be determined.
Preclinical EEG Findings May Inform Biomarker Development
An important component of the RTX-7340 development package involves neurophysiological research in Fmr1-knockout mice, an established experimental model used to investigate aspects of Fragile X syndrome.
According to the companies, studies involving PDE2 inhibition have demonstrated correction of disease-associated electroencephalography (EEG) abnormalities in these mice. EEG measures electrical activity in the brain and can provide information about patterns of neuronal activity and network function.
The findings may offer a basis for developing a translational biomarker strategy for RTX-7340. A biomarker is a measurable characteristic that can provide information about a biological process, disease state, or response to treatment. In drug development, biomarkers can help researchers determine whether a candidate is affecting its intended target or producing measurable changes in a relevant biological system.
For a neurological condition such as Fragile X syndrome, neurophysiological measurements could potentially complement conventional clinical assessments. These measurements may help researchers investigate whether changes in brain activity occur following treatment and whether such changes are associated with improvements in symptoms or functional outcomes.
Rumi Therapeutics intends to use the preclinical findings to inform the selection of neurophysiological measures for future clinical evaluation. The proposed strategy seeks to connect several stages of drug development: drug exposure, target occupancy, changes in brain activity, and potential clinical benefit.
Drug exposure refers to the amount of a therapeutic candidate available in the body over time. Target occupancy concerns the extent to which the drug engages its intended biological target. Measuring these factors alongside neurophysiological changes could help investigators determine whether the candidate reaches and affects the intended pathway and whether that activity corresponds to measurable effects on brain function.
However, a biomarker response alone would not establish clinical efficacy. Future studies would need to determine whether any treatment-associated changes in EEG or other neurophysiological measures are reproducible, clinically meaningful, and associated with outcomes that matter to individuals living with Fragile X syndrome.
Human Organoid Research May Strengthen Translational Evidence
Rumi Scientific Holdings combines Rumi Therapeutics with Rumi Scientific, whose proprietary human organoid platform supports disease modeling and therapeutic discovery.
Human organoids are three-dimensional, laboratory-grown biological structures designed to reproduce selected features of human tissues. Depending on their design and the cells used to develop them, organoids can help researchers study disease-associated biological processes in systems that may capture aspects of human biology not fully represented in conventional experimental models.
In neurodevelopmental drug research, human-relevant experimental systems may offer additional opportunities to investigate disease mechanisms, examine treatment responses, and explore whether findings from animal studies are consistent with observations in human-derived biological models.
The RTX-7340 program incorporates human organoid studies alongside its broader preclinical research package. The combination is intended to deepen the understanding of PDE2 inhibition and support the development of a strategy for evaluating the candidate in humans.
By integrating organoid research with neurophysiological endpoints, Rumi Scientific Holdings aims to strengthen the connection between laboratory observations and the design of clinical studies. These approaches could help researchers identify relevant biological effects and develop hypotheses about how those effects might relate to treatment outcomes.
Craig Ericksson, director of the Fragile X Syndrome Research and Treatment Center at Cincinnati Children’s Hospital, highlighted the importance of linking biological activity with outcomes that are meaningful to patients.
“A central challenge in Fragile X drug development is connecting a treatment’s effects on disease biology with outcomes that matter to patients. Combining human organoid research with neurophysiological measures creates an opportunity to build that connection more deliberately. A PDE2 program developed around this framework could help us evaluate both whether the drug affects relevant brain function and whether those effects translate into clinical benefit.”
The perspective underscores a key issue in Fragile X drug development. While laboratory studies may identify promising mechanisms and measurable biological changes, successful clinical translation requires evidence that these changes correspond to meaningful benefits for patients.
Human organoid studies and neurophysiological measurements may help inform this process, but they cannot independently establish whether RTX-7340 will be safe or effective in people.
Exploring Opportunities Beyond Fragile X Syndrome
Although RTX-7340 is initially being developed for Fragile X syndrome, Rumi Scientific plans to investigate the broader relevance of PDE2 inhibition in other neurodevelopmental disorders.
The rationale for this exploration stems from the role of intracellular signaling pathways in neuronal function. If PDE2 inhibition influences biological processes involved in synaptic communication and brain activity, researchers may investigate whether similar mechanisms are relevant to additional conditions.
However, neurodevelopmental disorders encompass a wide range of genetic causes, biological mechanisms, and clinical presentations. A therapeutic mechanism that demonstrates potential in one disease may not necessarily produce similar effects in another.
Further research will therefore be needed to establish which conditions, if any, could be appropriate for additional PDE2 inhibitor programs. Human organoid research and other disease-modeling approaches may help Rumi Scientific identify promising areas for investigation and assess the strength of the supporting evidence.
This broader research strategy could allow the company to use its scientific platform to evaluate opportunities beyond a single therapeutic indication while maintaining an initial focus on advancing RTX-7340 for Fragile X syndrome.
Next Steps for the RTX-7340 Program
The option-to-license agreement provides Rumi Therapeutics with an opportunity to advance RTX-7340 toward clinical evaluation using the preclinical evidence generated to date. The development program will need to progress through the applicable regulatory and clinical milestones before the candidate’s safety, tolerability, biological activity, and potential efficacy can be assessed in people.
Future development considerations include determining the appropriate clinical study design, selecting relevant outcome measures, evaluating neurophysiological biomarkers, and establishing how any measurable biological effects relate to clinical benefit.
For Fragile X syndrome, this work is particularly important because improvements in laboratory measures or brain activity may not automatically translate into changes in cognition, behavior, communication, or everyday functioning. Clinical research will be necessary to establish whether RTX-7340 can provide meaningful benefits and to characterize any associated risks.
The companies’ combined approach aims to address these challenges by integrating an IND-ready candidate with preclinical disease models, human organoid research, and a proposed translational biomarker strategy.
The agreement also represents a step in Rumi Scientific Holdings’ effort to connect its discovery capabilities with the development of therapeutic candidates. Its success will ultimately depend on the strength of the supporting evidence, the outcome of regulatory review, and the results of any future clinical studies.
RTX-7340 remains investigational. Its safety and efficacy in humans, including individuals with Fragile X syndrome, have not been established. The option-to-license agreement and the preclinical findings do not guarantee that the candidate will enter clinical trials or demonstrate a therapeutic benefit.
Nevertheless, the collaboration establishes a development pathway for further evaluating PDE2 inhibition as a potential treatment approach for Fragile X syndrome. By combining Enthorin Therapeutics’ RTX-7340 program with Rumi Scientific Holdings’ human organoid and translational research capabilities, the companies aim to build a stronger scientific foundation for determining whether the candidate’s preclinical effects can be translated into clinically meaningful outcomes.
About Fragile X Syndrome
Fragile X syndrome is a genetic neurodevelopmental disorder caused by changes in the FMR1 gene that reduce or eliminate production of functional FMRP, a protein important for brain development. It is a leading inherited cause of intellectual disability and can affect learning, language, attention, behavior, and social functioning.
About Rumi Scientific Holdings
Rumi Scientific Holdings includes Rumi Therapeutics and Rumi Scientific. Rumi Therapeutics develops therapies for neurological and neurodevelopmental disorders, while Rumi Scientific uses proprietary human organoid technology to study disease mechanisms and support therapeutic discovery.
About Enthorin Therapeutics
Enthorin Therapeutics is a clinical stage pharmaceutical company founded with the goal of developing innovative therapeutics that target brain circuit dysfunction to improve quality of life for patients, families, and communities. Learn more at www.enthorin.com.
About Liberi Group
Rumi Scientific was supported in its engagement with Enthorin Therapeutics by Liberi Group, a global life sciences business development consultancy serving as Rumi Scientific’s BD advisor. Liberi Group is a global business development and strategic consultancy focused on the life sciences and biotech industries. For more information, please visit www.liberigroup.com.